Insmed Analyst Price Targets - Benzinga

Insmed Inc

INSMNASDAQ

Trade with Public

Trade with Public

$103.36

-1.88-1.78%

最終更新: Oct 7, 10:41 AM

$103.94

-1.29-1.23%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Insmed Analyst Price Targets - Benzinga

Insmed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Insmed (INSM).

Price Target Range — 7 Quarters

Analyst Consensus — 21 Analysts

21Buy

Consensus RatingBuy# Analysts21Avg. Consensus PT$197Upside to Avg. PT+90.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$237→$207
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$188
Sep 15, 2026	Roth Capital	Adam Walsh	PT Cut	Buy	$212→$198
Aug 10, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$179→$175
Aug 10, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$185→$195
Aug 7, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$207→$205
Aug 7, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$161→$169
Aug 7, 2026	Evercore ISI Group	Josh Schimmer	PT Raise	Outperform	$160→$170
Jul 21, 2026	BMO Capital	Connor Mackay	Initiate	Outperform	$192
Jul 15, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$160→$161
Jul 10, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$207
Jun 22, 2026	Evercore ISI Group	Josh Schimmer	PT Cut	Outperform	$162→$160
Jun 8, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$180→$179
Jun 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$205→$195
May 14, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$205→$185
May 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$220→$205
May 8, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$177→$160
May 8, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$230→$226
Apr 17, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$212
Apr 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$212→$216

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Insmed, Lowers Price Target to $207

Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Insmed (NASDAQ:INSM) with a Buy and announces $188 price target.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198

Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195

Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.

Benzinga Newsdesk